Cargando…

Response to treatment of hepatitis C in HCV/HIV co-infected patients is not influenced by either abacavir or tenofovir with weight-based ribavirin

Detalles Bibliográficos
Autores principales:	Bhatti, L, Shah, S, Khanlou, H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112996/ http://dx.doi.org/10.1186/1758-2652-13-S4-P211

Ejemplares similares

Role of platelet activation in the cardiovascular complications associated with HIV infection: differential effect of abacavir versus tenofovir
por: Francisci, D, et al.
Publicado: (2010)

LB-7. Weight Change in Suppressed People with HIV (PWH) Switched from Either Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) to Tenofovir Alafenamide (TAF)
por: Sax, Paul, et al.
Publicado: (2020)

Sustained virological response in HIV/HCV co-infected patients without rapid virological response (RVR) on peginterferon-ribavirin therapy
por: Labarga, P, et al.
Publicado: (2010)

Abacavir forms novel cross-linking abacavir protein adducts in patients
por: Meng, Xiaoli, et al.
Publicado: (2014)

Chronic HCV treatment with peginterferon-ribavirin and severe tuberculosis re-activation
por: Manfredi, Roberto, et al.
Publicado: (2010)

Platelet activity in HIV-infected patients on abacavir-containing antiretroviral therapy
por: Palacios, R, et al.
Publicado: (2010)

Long-term outcomes of switching to fixed-dose abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC): 3-year results of the BICOMBO study
por: Martínez, E, et al.
Publicado: (2010)

Boceprevir (BOC) and Telaprevir (TPV) therapeutic drug monitoring in HCV and HIV-HCV infected patients treated with triple therapy Ribavirine/Peg-interferon/Boceprevir or Telaprevir: impact of the antiretroviral (ARV) treatment
por: Chantry, AS, et al.
Publicado: (2014)

Hepatitis C virus (HCV) infection and re-infection among HCV- and HIV/HCV-infected injection drug users
por: Conway, B, et al.
Publicado: (2010)

48 week bone marker changes with Dolutegravir (DTG) plus Abacavir/Lamivudine (ABC/3TC) vs. Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): the SINGLE trial
por: Yazdanpanah, Y, et al.
Publicado: (2014)

Severe psoriasis emerged after treatment of chronic HCV co-infection with pegylated-interferon and ribavirin, supported by neutropenia rescue with repeated filgrastim administration
por: Manfredi, Roberto, et al.
Publicado: (2010)

Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord
por: Smit, Colette, et al.
Publicado: (2015)

An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine
por: Rogatto, Felipe, et al.
Publicado: (2014)

Evaluation of cardiovascular biomarkers In HIV-infected patients switching to abacavir or tenofovir based therapy
por: Rasmussen, Thomas A, et al.
Publicado: (2011)

Spontaneous HCV clearance in a patient with HIV infection and a concurrent, never treated, evolutive HCV hepatitis, after over twenty years of chronic co-infection
por: Manfredi, Roberto, et al.
Publicado: (2010)

The study of hepatitis B surface antigen and anti-HCV in HIV infected patients
por: Girish, N, et al.
Publicado: (2012)

Interactions of Tenofovir, Lamivudine, Abacavir and Didanosine in Primary Human Cells
por: Janneh, Omar, et al.
Publicado: (2011)

Pharmacokinetics of lamivudine, abacavir and zidovudine administered twice daily as syrups versus scored tablets in HIV-1-infected Ugandan children
por: Gitta, PK, et al.
Publicado: (2010)

1028. Long-term Follow-up After a Switch to Bictegravir, Emtracitabine, Tenofovir Alafenamide from Dolutegravir, Abacavir, Lamivudine
por: Brar, Indira, et al.
Publicado: (2020)

Efficiency of HIV-1 PR-RT genotyping is not impacted by co-infection with HCV
por: Deloof, ACA, et al.
Publicado: (2010)

Efficacy and Tolerability of RAL, MVC and ETV used in combination in the treatment of highly treatment experienced HIV infected patients
por: Khanlou, Homayoon, et al.
Publicado: (2010)

Hepatitis C virus core protein substitutions affect the response to pegylated-interferon and ribavirin therapy
por: Alhamlan, Fatimah S, et al.
Publicado: (2014)

Neuro-biological inferences into the depressive disorders of patients with chronic hepatitis C treated with interferon and ribavirin
por: Hurezeanu, Dan, et al.
Publicado: (2014)

Intracellular tenofovir-diphosphate accumulation in an HIV-infected patient with Fanconi syndrome and osteomalacia
por: Haverkort, ME, et al.
Publicado: (2010)

Immune response characterization in HIV/HCV co-infected patients of medicine tropical foundation
por: Malheiro, Adriana, et al.
Publicado: (2010)

Behavioral factors associated with HCV and HIV co-infection in residents of São Paulo, Brazil
por: Farias, Norma, et al.
Publicado: (2012)

Evaluation of a pharmacogenetic test in Thailand for abacavir hypersensitivity screening in human immunodeficiency virus infection
por: Chonlaphat, Sukasem, et al.
Publicado: (2014)

Macromolecular prodrugs of ribavirin: towards a treatment for co-infection with HIV and HCV
por: Smith, Anton A. A., et al.
Publicado: (2015)

Renal Function Declines More in Tenofovir- than Abacavir-Based Antiretroviral Therapy in Low-Body Weight Treatment-Naïve Patients with HIV Infection
por: Nishijima, Takeshi, et al.
Publicado: (2012)

Tenofovir use is associated with low vitamin D levels in a Spanish HIV cohort
por: Cervero, M, et al.
Publicado: (2010)

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
por: Kawuma, Aida N., et al.
Publicado: (2023)

Effects on insulin sensitivity and hepatic safety of Atazanavir in HCV/HIV coinfected patients versus HIV monoinfected: A prostective 48-week study
por: Meijide, Héctor, et al.
Publicado: (2010)

Changes in Bone Turnover and Bone Loss in HIV-Infected Patients Changing Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine
por: Haskelberg, Hila, et al.
Publicado: (2012)

Predictors of Limb Fat Gain in HIV Positive Patients Following a Change to Tenofovir-Emtricitabine or Abacavir-Lamivudine
por: Martin, Allison, et al.
Publicado: (2011)

Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients
por: Hatu, Giorgiana, et al.
Publicado: (2014)

Low reduction of HCV-RNA level at week 4 in HIV-1 infected patients with acute HCV Infection
por: Vincent, A, et al.
Publicado: (2012)

1041. Tenofovir alafenamide associated weight change in persons living with HIV
por: Crowder, Carlysle E, et al.
Publicado: (2020)

Liver disease progression in HIV/HCV co-infected patients: a role for metalloproteinases and their specific inhibitors
por: Sasongko, Priyo
Publicado: (2006)

Development of a test system for simultaneous detection of HIV RNA and Hepatitis C virus (HCV) and DNA of Hepatitis B virus (HBV) in blood samples
por: Shahrokhi, Nader, et al.
Publicado: (2010)

Efficacy and safety of hepatitis C direct-acting protease inhibitors (DAA-PI ) in real life in HIV-HCV coinfected patients
por: Ménard, A, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_v58iusboi8roco6kua9hakk6dj